Compare CVM & MLSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVM | MLSS |
|---|---|---|
| Founded | 1983 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 22.1M |
| IPO Year | 1996 | 1996 |
| Metric | CVM | MLSS |
|---|---|---|
| Price | $1.66 | $0.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 153.6K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $264,033.00 | ★ $8,973,982.00 |
| Revenue This Year | N/A | $12.64 |
| Revenue Next Year | N/A | $8.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.45 | 3.99 |
| 52 Week Low | $0.23 | $0.22 |
| 52 Week High | $13.48 | $1.05 |
| Indicator | CVM | MLSS |
|---|---|---|
| Relative Strength Index (RSI) | 24.76 | 63.39 |
| Support Level | N/A | $0.24 |
| Resistance Level | $4.84 | $0.40 |
| Average True Range (ATR) | 0.32 | 0.03 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 3.25 | 94.50 |
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.